Alopecia clinical trials
30 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- Dupilumab in the Treatment of Pediatric Alopecia Areata
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Intralesional Cyclosporine for Alopecia Areata
- A Study of LAD603 in Adults With Alopecia Areata
- Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
- Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
- Regeneron AA Multicenter (Dupilumab)
- Effects of KSM-66 Ashwagandha® (300 mg) on Skin and Hair Health in Healthy Men and Women"
- HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- Autologous Adipose Cells Therapy
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
- Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
- Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
- Blood Specimen Collection For Laboratory Assay Research
- Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
- Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
- A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
- A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
- Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Alopecia” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.